Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Heterogeneity Assessment in mCRPC with 177Lu-PSMA-617
NCT06706921Phase 4Recruiting
- Sponsor
- VA Greater Los Angeles Healthcare System
- Start
- Dec 2024
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by VA Greater Los Angeles Healthcare System. Primary endpoint: 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer at 34 weeks. Started Dec 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06706921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706921.